cells

Scientific Advisory Board

Jeffrey Bluestone

Jeffrey A. Bluestone, PhD

Dr. Bluestone serves as the chairman of Arcus’s Scientific Advisory Board. He is CEO and President of Sonoma Biotherapeutics and A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology at University of California, San Francisco.

arrow
Christopher Garcia

Christopher Garcia, PhD

Dr. Garcia is an investigator at the Howard Hughes Medical Institute. He also serves as a professor at the Stanford University School of Medicine across 2 departments (Molecular and Cellular Physiology and Structural Biology).

arrow
Ramy Ibrahim

Ramy Ibrahim, MD

Dr. Ibrahim is the Chief Medical Officer of the Parker Institute for Cancer Immunotherapy. He is a recognized leader of clinical development and immunotherapy who has helped develop some of the first breakthrough treatments in the field.

arrow
David Lacey

David Lacey, MD

Dr. Lacey is the retired former SVP of Discovery Research at Amgen. At the end of his tenure he oversaw a research organization of approximately 1200 encompassing four broad therapeutic areas: inflammation, oncology, metabolic disorders and neurosciences.

arrow
Antoni Ribas

Antoni Ribas, MD, PhD

Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research to understand how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered T cells, and BRAF-targeted therapies.

arrow
Stefani Spranger

Stefani Spranger, PhD

Dr. Spranger is currently an Assistant Professor of Biology at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. She researches the interactions between cancer and the immune system,

arrow